US Drug Recall Register
Class II · Moderate risk Ongoing Initiated May 29, 2013 (13 years ago)

Progesterone 100 mg/ml in Olive Oil Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

What was recalled

Progesterone 100 mg/ml in Olive Oil Injection, compounded by Olympia Pharmacy, Orlando, FL

Recalling firm
Lowlite Investments, Inc. D/B/A Olympia Pharmacy
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-776-2013

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Progesterone recalls

See all
Class II · Moderate risk Ongoing

Medroxyprogesterone Acetate Injectable Suspension

Reason Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Mckesson Medical-Surgical Inc. Corporate Office NDC 55150-0330-01 D-0400-2025
Class II · Moderate risk Ongoing

Progesterone Injection USP

Reason Presence of Particulate Matter: A market complaint was received of a glass piece in the vial.

Eugia US LLC NDC 55150-306-10 D-0186-2025
Class II · Moderate risk Ongoing

Progesterone Injection

Reason Presence of Particulate Matter: Complaint received of a glass particle in the vial.

Eugia US LLC NDC 55150-306-10 D-0624-2024
Class II · Moderate risk Completed

Progesterone 200 mg

Reason Presence of Foreign Substance; Broken metal piece found embedded in tablet.

Coast Quality Pharmacy, LLC dba Anazao Health D-0563-2024